Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.
about
Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson's DiseaseA Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.Associations of hippocampal subfields in the progression of cognitive decline related to Parkinson's disease.The Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats.Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
P2860
Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Glutamatergic pathways as a ta ...... nesias in Parkinson's disease.
@ast
Glutamatergic pathways as a ta ...... nesias in Parkinson's disease.
@en
type
label
Glutamatergic pathways as a ta ...... nesias in Parkinson's disease.
@ast
Glutamatergic pathways as a ta ...... nesias in Parkinson's disease.
@en
prefLabel
Glutamatergic pathways as a ta ...... nesias in Parkinson's disease.
@ast
Glutamatergic pathways as a ta ...... nesias in Parkinson's disease.
@en
P2860
P356
P1476
Glutamatergic pathways as a ta ...... nesias in Parkinson's disease.
@en
P2093
M Angela Cenci
P2860
P304
P356
10.1042/BST20140006
P577
2014-04-01T00:00:00Z